Results
1 -
4 of
4
(Click
here to explore results)
- Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases. Thomas Beckers, Siavosh Mahboobi, Andreas Sellmer, Matthias Winkler, Emerich Eichhorn, Herwig Pongratz, Thomas Maier, Thomas Ciossek, Thomas Baer, Gerhard Kelter, Heinz-Herbert Fiebig, Mathias Schmidt
, Med. Chem. Commun.
, 2012
, 3
, 829
- Development of second generation epigenetic agents. Philip Jones
, Med. Chem. Commun.
, 2012
, 3
, 135
- Discovery of a pair of diastereomers as potent HDACs inhibitors: determination of absolute configuration, biological activity comparison and computational study. Yingjie Zhang, Elizabeth S. Inks, Mengyuan Zhu, C. James Chou, Hao Fang, Minyong Li, Yuemao Shen, Fan Yi, Wenfang Xu
, RSC Adv.
, 2013
, 3
, 21106
- Developing novel non-hydroxamate histone deacetylase
inhibitors: the chelidamic warhead. Sergio Valente, Mariarosaria Conte, Maria Tardugno, Angela Nebbioso, Gabriella Tinari, Lucia Altucci, Antonello Mai
, Med. Chem. Commun.
, 2012
, 3
, 298